These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38310108)

  • 1. Local structural preferences in shaping tau amyloid polymorphism.
    Louros N; Wilkinson M; Tsaka G; Ramakers M; Morelli C; Garcia T; Gallardo R; D'Haeyer S; Goossens V; Audenaert D; Thal DR; Mackenzie IR; Rademakers R; Ranson NA; Radford SE; Rousseau F; Schymkowitz J
    Nat Commun; 2024 Feb; 15(1):1028. PubMed ID: 38310108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tau strains shape disease.
    Vaquer-Alicea J; Diamond MI; Joachimiak LA
    Acta Neuropathol; 2021 Jul; 142(1):57-71. PubMed ID: 33830330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based inhibitors halt prion-like seeding by Alzheimer's disease-and tauopathy-derived brain tissue samples.
    Seidler PM; Boyer DR; Murray KA; Yang TP; Bentzel M; Sawaya MR; Rosenberg G; Cascio D; Williams CK; Newell KL; Ghetti B; DeTure MA; Dickson DW; Vinters HV; Eisenberg DS
    J Biol Chem; 2019 Nov; 294(44):16451-16464. PubMed ID: 31537646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies.
    Irwin DJ; Cohen TJ; Grossman M; Arnold SE; Xie SX; Lee VM; Trojanowski JQ
    Brain; 2012 Mar; 135(Pt 3):807-18. PubMed ID: 22366796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.
    Soleimani-Meigooni DN; Iaccarino L; La Joie R; Baker S; Bourakova V; Boxer AL; Edwards L; Eser R; Gorno-Tempini ML; Jagust WJ; Janabi M; Kramer JH; Lesman-Segev OH; Mellinger T; Miller BL; Pham J; Rosen HJ; Spina S; Seeley WW; Strom A; Grinberg LT; Rabinovici GD
    Brain; 2020 Dec; 143(11):3477-3494. PubMed ID: 33141172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chaperoning shape-shifting tau in disease.
    Ryder BD; Wydorski PM; Hou Z; Joachimiak LA
    Trends Biochem Sci; 2022 Apr; 47(4):301-313. PubMed ID: 35045944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioflavin S Staining and Amyloid Formation Are Unique to Mixed Tauopathies.
    Fiock KL; Betters RK; Hefti MM
    J Histochem Cytochem; 2023 Feb; 71(2):73-86. PubMed ID: 36861683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropathological correlates of structural and functional imaging biomarkers in 4-repeat tauopathies.
    Spina S; Brown JA; Deng J; Gardner RC; Nana AL; Hwang JL; Gaus SE; Huang EJ; Kramer JH; Rosen HJ; Kornak J; Neuhaus J; Miller BL; Grinberg LT; Boxer AL; Seeley WW
    Brain; 2019 Jul; 142(7):2068-2081. PubMed ID: 31081015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The structure and phase of tau: from monomer to amyloid filament.
    Zeng Y; Yang J; Zhang B; Gao M; Su Z; Huang Y
    Cell Mol Life Sci; 2021 Mar; 78(5):1873-1886. PubMed ID: 33078207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human tauopathy-derived tau strains determine the substrates recruited for templated amplification.
    Tarutani A; Miyata H; Nonaka T; Hasegawa K; Yoshida M; Saito Y; Murayama S; Robinson AC; Mann DMA; Tomita T; Hasegawa M
    Brain; 2021 Sep; 144(8):2333-2348. PubMed ID: 33693528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
    Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
    Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-Associated Mutations in Tau Encode for Changes in Aggregate Structure Conformation.
    Sun KT; Patel T; Kang SG; Yarahmady A; Srinivasan M; Julien O; Heras J; Mok SA
    ACS Chem Neurosci; 2023 Dec; 14(24):4282-4297. PubMed ID: 38054595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated.
    Robinson JL; Lee EB; Xie SX; Rennert L; Suh E; Bredenberg C; Caswell C; Van Deerlin VM; Yan N; Yousef A; Hurtig HI; Siderowf A; Grossman M; McMillan CT; Miller B; Duda JE; Irwin DJ; Wolk D; Elman L; McCluskey L; Chen-Plotkin A; Weintraub D; Arnold SE; Brettschneider J; Lee VM; Trojanowski JQ
    Brain; 2018 Jul; 141(7):2181-2193. PubMed ID: 29878075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asparagine residue 368 is involved in Alzheimer's disease tau strain-specific aggregation.
    Shimonaka S; Matsumoto SE; Elahi M; Ishiguro K; Hasegawa M; Hattori N; Motoi Y
    J Biol Chem; 2020 Oct; 295(41):13996-14014. PubMed ID: 32759167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations causing neurodegenerative tauopathies.
    Goedert M; Jakes R
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):240-50. PubMed ID: 15615642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-Linking Mass Spectrometry Analysis of Metastable Compact Structures in Intrinsically Disordered Proteins.
    Chen D; Joachimiak LA
    Methods Mol Biol; 2023; 2551():189-201. PubMed ID: 36310204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural Identification of Individual Helical Amyloid Filaments by Integration of Cryo-Electron Microscopy-Derived Maps in Comparative Morphometric Atomic Force Microscopy Image Analysis.
    Lutter L; Al-Hilaly YK; Serpell CJ; Tuite MF; Wischik CM; Serpell LC; Xue WF
    J Mol Biol; 2022 Apr; 434(7):167466. PubMed ID: 35077765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro amplification of pathogenic tau conserves disease-specific bioactive characteristics.
    Xu H; O'Reilly M; Gibbons GS; Changolkar L; McBride JD; Riddle DM; Zhang B; Stieber A; Nirschl J; Kim SJ; Hoxha KH; Brunden KR; Schellenberg GD; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2021 Feb; 141(2):193-215. PubMed ID: 33385254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.
    Stamelou M; Respondek G; Giagkou N; Whitwell JL; Kovacs GG; Höglinger GU
    Nat Rev Neurol; 2021 Oct; 17(10):601-620. PubMed ID: 34426686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.